

Substitute for form 1449/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>			Complete If Known Application Number 10/593,691-Conf. #3128 Filing Date December 4, 2006 First Named Inventor Ayumu KURIMOTO Art Unit 1624 Examiner Name M. L. Berch Attorney Docket Number 0020-5516PUS1		
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-2003/0105323-A1	06-05-2003	Fujita et al.	
	AB*	US-6,951,866-B2	10-04-2005	Fujita et al.	
	AC*	US-6,458,798-B1	10-01-2002	Fujita et al.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-Issue number(s), publisher, city and/or country where published.	†
	CA	U.S. Provisional Appl. No. 60/937,726 filed June 29, 2007 (priority document of US-2009/0047249-A1, Appl. No. 12/215,598).	
	CB	Aoki et al., "Weekly Dosing of AZD8848/DSP-3025, A Novel TLR7 Agonist Antedrug, Demonstrates a Prolonged Period of Control Against Markers of Pulmonary Inflammation in an Allergen Challenge Model in the Mouse", ATS New Orleans, May 2010, Abstract 529 Poster, Pharmacology Research Laboratories, Daiinippon Sumitomo Pharma Co., Ltd., Osaka, Japan, Bioscience, AstraZeneca R&D Charnwood, Loughborough, England.	
	CC	Asthma, MDAdvice.com, http://www.mdadvice.com/topics/asthma/info/1.htm (downloaded June 24, 2010).	
	CD	Australian Office Action dated May 4, 2010 for Appl. No. 2005226359.	
	CE	Beil et al., "AZD8848/DSP-3025, A Novel Potent TLR7 Agonist Antedrug, Demonstrates Negligible Systemic Activity and a Prolonged Period of Control After Cessation of Weekly Dosing in a Brown Norway Rat Ovalbumin Challenge Model", ATS New Orleans, May 2010, Abstract 291 Poster, Bioscience, AstraZeneca R&D Charnwood, Loughborough, England, Discovery DMPK, AstraZeneca R&D Charnwood, Loughborough, England, Pharmacology Research Laboratories, Daiinippon Sumitomo Pharma Co., Ltd., Osaka, Japan.	
	CF	Biffen et al., "Biological Activity of a Novel TLR7 Agonist Antedrug for the Treatment of Allergic Diseases", ATS New Orleans, May 2010, Abstract 649 Poster, Bioscience, AstraZeneca R&D Charnwood, Loughborough, England, Pharmacology Research Laboratories, Daiinippon Sumitomo Pharma Co., Ltd., Osaka, Japan.	
	CG	Chronic obstructive pulmonary disease, AllRefer.com, http://health.allrefer.com/health/chronic_obstructive_pulmonary_disease_prevention.html (downloaded June 24, 2010).	
	CH	Ikedo et al., "AZD8848/DSP-3025, A Novel Potent TLR7 Agonist Antedrug, Demonstrates Efficacy Against Airway Obstruction and Other Inflammatory Endpoints in Guinea Pig Models of Rhinitis and Asthma with Acute and Weekly Dosing", ATS New Orleans, May 2010, Abstract 786 Poster, Pharmacology Research Laboratories, Daiinippon Sumitomo Pharma Co., Ltd., Osaka, Japan, Bioscience, AstraZeneca R&D Charnwood, Loughborough, England.	

Examiner Signature	Date
	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied under 37 CFR 1.86(a)(2)(ii) because that application was filed after June 30, 2003 or is available in the PVP. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/593,691-Conf. #3128
		Filing Date	December 4, 2006
		First Named Inventor	Ayumu KURIMOTO
		Art Unit	1624
		Examiner Name	M. L. Berch
Sheet	2	of	2
		Attorney Docket Number	0020-5516PUS1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Volume-issue number(s), publisher, city and/or country where published.	T ²
	CI	Laino, C., "In Small Study, Imaging Detects Lung Damage in People Exposed to Secondhand Smoke", Oncology Times, Vol. 30, No. 2, pp. 15, 2008.	
	CJ	Matsui et al., "Mechanisms of Inhibition of Type-2 Cytokines by Novel TLR7 Agonist Antedrug", ATS New Orleans, May 2010, Abstract 787 Poster, Pharmacology Research Laboratories, Daiinippon Sumitomo Pharma Co., Ltd., Osaka, Japan, Bioscience, AstraZeneca R&D Charnwood, Loughborough, England.	
	CK	McInally et al., "Identification of a Novel TLR7 Agonist Antedrug", Poster, Medicinal Chemistry, AstraZeneca R&D Charnwood, Loughborough, England, Chemistry Research Laboratories, Daiinippon Sumitomo Pharma Co., Ltd., Osaka, Japan, EFMC-ISMC 201, Brussels, Belgium, Sept. 5-9, 2010.	
	CL	Respiratory Experts Call for Global Approach to Treat Chronic Disease, MedWire News, http://www.medwire-news.md/48/64443/Respiratory_experts_call_for_Global_Approach_to_Treat_Chronic_Disease.html , 2007.	
	CM	Tojo et al., "Synthesis and Biological Evaluation of a Novel TLR7 Agonist with an Antedrug Strategy", Poster, Chemistry Research Laboratories, Daiinippon Sumitomo Pharma Co., Ltd., Osaka, Japan, Medicinal Chemistry, AstraZeneca R&D Charnwood, Loughborough, England, EFMC-ISMC 201, Brussels, Belgium, Sept. 5-9, 2010.	

Examiner Signature	Date Considered
-----------------------	--------------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied under 37 CFR 1.98(a)(2)(iii) because that application was filed after June 30, 2003 or is available in the IFW. ³ Applicant's unique citation designation number (optional). ⁴ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁵ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁷ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language translation is attached.